Proteon Therapeutics Email Format

Biotechnology ResearchUnited States11-50 Employees

Proteon Therapeutics is a United States based biotechnology research company focused on kidney and vascular diseases. Its lead therapeutic candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to address the vessel injury responses that can lead to blockages and reduced blood flow. The company is advancing vonapanitase through two Phase 3 trials, PATENCY-1 and PATENCY-2, in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. It has also completed a Phase 1 study in patients with symptomatic peripheral artery disease.

As a small biotechnology organization, Proteon operates in the research sector with a focus on therapies for vascular and kidney-related conditions. Its work targets clinicians and patients affected by CKD-related vascular access and other vascular diseases, with the Phase 3 program highlighting its emphasis on late-stage development.

Sign up for free to view info

Company overview Employee directory